Overview

Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Stage Iļ¼špreoperative therapy - Capecitabine plus oxaliplatin with herceptin is superior to surgery alone for patients with potentially resectable HER-2 positive gastric cancer with liver metastasis; Stage II: Perioperative therapy - Perioperative Capecitabine plus oxaliplatin with herceptin is superior to adjuvant Capecitabine plus oxaliplatin alone for patients with potentially resectable HER-2 positive gastric cancer with liver metastasis;
Phase:
Phase 4
Details
Lead Sponsor:
Hebei Medical University
Treatments:
Capecitabine
Oxaliplatin
Trastuzumab